What Happened?
Fargo, ND-based ImmunoPrecise-Antibodies Appointed Kristin Taylor as Interim Chief Financial Officer
About the Company
IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry`s most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome.
About the Person
Kristin Taylor is Interim Chief Financial Officer at ImmunoPrecise Antibodies. Previously, Kristin held various senior HR leadership roles in the industry.
Info Source
News
Short Profile